羟苯磺酸钙治疗糖尿病视网膜病变血浆ET-1和CGRP的变化研究

Changes of plasma endothelin-1 （ET-1） and calcitonin gene related peptide （CGRP） of calcium dobesilate in treatment of diabetic retinopathy

目的观察羟苯磺酸钙治疗糖尿病视网膜病变（DR）患者血浆内皮素1（ET-1）、降钙素基因相关肽（CGRP）含量的动态变化。方法自身前后对照方法。羟苯磺酸钙治疗100例DR患者，应用放射免疫分析（RIA）检测患者血浆ET-1、CGRP的浓度。观察时间分为服用药物前和服药后2周、1月、3月、半年共5个时间点。结果DR患者服用药物前血浆ET-1、CGRP含量分别为（186．15±43．89）ng/L、（46．37±13．28）ng/L。服用药物治疗后不同时间（2周、1月、3月、6月）ET-1含量分别为（153．82±39．54）、（121．27±38．45）、（72．61±30．24）和（71．89±24．37）ng／L；CGRP含量分别为（43．42±12．78）、（59．65±15．72）、（68．87±25．36）和（67．91±24．75）ng/L。结果显示，羟苯磺酸钙治疗后，患者血浆ET-1、CGRP含量发生变化，ET-1降低，CGRP升高，ET-1／CGRP比值降低接近正常水平。结论提示血浆ET-1、CGRP在羟苯磺酸钙治疗DR可能起着重要的病理作用，其对DR诊治疗效的随访判定有一定的应用参考价值。

Objective To observe the changes of plasma endothelin-1 （ET-1） and calcitonin gene related peptide （CGRP） of calcium dobesilate in treatment of diabetic retinopathy （DR）. Methods This is a self-control trial. Plasma ET-1 and CGRP concentrations were measured with RIA in 100 patients with DR received calcium dobesilate （pretherapy, post-treatment： 2w, lm, 3m and 6m）. Results The content of plasma ET-1 were 186.15±43.89, 153.82±39.54, 121.27±38.45, 72.61±30.24 and 71.89±24.37ng/L at pretherapy and post-treatment （2w, 1 m, 3m, 6m）, respectively; that of plasma CGRP were 46.37±13.28, 43.42±12.78, 59.65±15.72, 68.87±25.36 and 67.91±24.75ng/L. After receiving the treatment with calcium dobesilate, the content of plasma ET-1 decreased and CGRP increased gradually. Conclusions Plasma ET-1 and CGRP play an important role in the whole patho-physiologic process in the DR treatment with calcium dobesilate, and measurement of their plasma concentrations may predict the curative effect On the DR follow-up.